486 related articles for article (PubMed ID: 31548347)
41. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
Liu Z; Deng M; Wu L; Zhang S
Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
[TBL] [Abstract][Full Text] [Related]
42. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
[TBL] [Abstract][Full Text] [Related]
43. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
44. The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
Shaverdian N; Offin M; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Hellmann MD; Rimner A; Paik PK; Chaft JE; Gomez DR
J Thorac Oncol; 2021 Aug; 16(8):1392-1402. PubMed ID: 33992811
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
[TBL] [Abstract][Full Text] [Related]
46. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
47. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
48. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
Hu L; Miao W; Loignon M; Kandouz M; Batist G
Cancer Chemother Pharmacol; 2010 Aug; 66(3):467-74. PubMed ID: 19940992
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
50. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
51. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
52. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
53. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
Rosell R; Felip E
Semin Oncol; 2001 Aug; 28(4 Suppl 14):37-44. PubMed ID: 11605182
[TBL] [Abstract][Full Text] [Related]
54. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
55. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
56. Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report.
Nishimura R; Yoshida T; Torasawa M; Kashihara T; Ohe Y
Thorac Cancer; 2023 Jan; 14(2):206-209. PubMed ID: 36453575
[TBL] [Abstract][Full Text] [Related]
57. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
[TBL] [Abstract][Full Text] [Related]
58. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
[TBL] [Abstract][Full Text] [Related]
59. Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.
Sumii M; Namba M; Tokumo K; Yamauchi M; Okamoto W; Hattori N; Sugiyama K
Intern Med; 2023 Oct; 62(20):3001-3004. PubMed ID: 36858519
[TBL] [Abstract][Full Text] [Related]
60. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]